HOTAIRM1 and acute myeloid leukemia: These findings suggest that the investigated markers, particularly HOTAIRM1, HOXA9, and GFI1, may serve as potential clinical biomarkers for monitoring AML progression and could be valuable targets for early detection or therapeutic intervention.